- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02336997
Evaluation of the Effect of Autologous Fat and SVF Transplantation in Promoting Mechanical-stretch Induced in Vivo Skin Regeneration
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Reconstruction of large scale skin defect is a challenge to clinical surgeons. Soft tissue expansion has won wide attention in recent years as it promotes skin regeneration with perfectly matched tissue. However, some patients with poor skin regenerative ability would suffer from skin flap over-thinned and even necrosis under the continuous stretching by silicone expander. This study is to evaluate the effects of autologous fat graft/SVF transplantation on accelerating skin regeneration and promoting tissue expansion process.
Patients aged between 18 to 60 years old who appear with deteriorated expanded skin will be enrolled and randomized into three groups, named as the experimental group and the control group. Patients from the FAT-GRAFT group will have a liposuction and subdermal fat graft transplantation. Patients from the SVF-TRANSPLANTATION group will have a liposuction and SVF will be separated and transplanted intradermally to expanded skin. Patients from the control group will have saline injection.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Qing-Feng Li, M.D., Ph.D.
- Phone Number: 00862123271699
Study Locations
-
-
-
Shanghai, China
- Recruiting
- Shanghai Ninth People's Hospital
-
Contact:
- Qing-Feng Li, M.D., Ph.D.
-
-
Shanghai
-
Shanghai, Shanghai, China, 200011
- Recruiting
- Shanghai Ninth People's Hospital, Affliated to Shanghai Jiao Tong University School of Medicine
-
Contact:
- Qingfeng Li, MD, PhD
- Phone Number: 0086 21 63089567
- Email: liqfliqf@yahoo.com.cn
-
Contact:
- Shuangbai Zhou, MD
- Phone Number: 0086 13482514585
- Email: shuangbaizhou@gmail.com
-
Principal Investigator:
- Qingfeng Li, MD, PhD
-
Sub-Investigator:
- Shuangbai Zhou, MD
-
Sub-Investigator:
- Yun Xie, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Inclusion Criteria:
- Age of 18 to 60 years;
- Expanding skin donor site at the face, neck, anterior chest wall, abdominal wall or back;
- Implanted silicone expander of 80 to 600 ml in size;
- History of deterioration in the expanded skin texture that did not improve after the inflation procedure was suspended for more than 2 weeks;
- Persistent high level of expander internal pressure;
- Need for further skin expansion;
Exclusion Criteria:
- Not fit for soft tissue expansion treatment;
- Evidence of infection, ischemia, ulcer or other pathological changes within the targeting area which defined as not suitable for expansion; or history of delayed healing, radiational therapy;
- Significant renal, cardiovascular, hepatic and psychiatric diseases;
- Significant medical diseases or infection (including but not limited to the carrier of hepatitis B virus or HIV)
- BMI >30;
- History of any hematological disease, including leukopenia , thrombocytopenia, or thrombocytosis;
- History of allogenic bone marrow transplantation;
- Long history of smoking;
- Evidence of malignant diseases or unwillingness to participate.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: FAT-GRAFT
Fat graft transplantation
|
Liposuction will be performed and autologous fat graft will be harvest after washing with saline.
Patients will receive autologous fat graft transplantation subdermally to expanded skin at the density of 0.1 ml/cm2.
|
Experimental: SVF-TRANSPLANTATION
Transplantation of resuspended SVF
|
Liposuction will be performed.
SVF will be separated from autologous fat graft by collagenase digestion.
Patients will receive resuspended SVF transplantation subdermally to expanded skin at the density of 1*10e6 cells/cm2.
|
Placebo Comparator: CONTROL
Same volume saline injection
|
Saline will be injected into expanded skin.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Occurence of Major Adverse Events
Time Frame: Up to approximately 24 months after study start
|
Including expanded flap ischaemia, necrosis, fluidify, infection, and all other adverse events
|
Up to approximately 24 months after study start
|
To Measure the Change in Inflation Volume of the Silicone Expander from Baseline at 8 weeks
Time Frame: baseline and 8 weeks post treatment
|
Record the inflation volume of each expander with the maintained inner pressure.
|
baseline and 8 weeks post treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To Measure the Size of Expanded Flap with 3D laser scanner and calculate the surface of expanded skin
Time Frame: baseline and 8 weeks post treatment
|
Record the outface of expanded skin flap with 3D laser scanner and calculate the surface of expanded skin
|
baseline and 8 weeks post treatment
|
To Measure the Texture of Expanded Flap with VISIA scanner
Time Frame: 4 weeks and 8 weeks post treatment
|
Evaluate skin texture with VISIA scanner and compare the characteristics
|
4 weeks and 8 weeks post treatment
|
To Measure Expanded Skin Thickness by Ultrasound Scanning
Time Frame: baseline, 4 weeks and 8 weeks post treatment
|
Measure the dermal and epidermal thickness of expanded skin by ultrasound scanning
|
baseline, 4 weeks and 8 weeks post treatment
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- [2014]47
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Scar
-
University of California, DavisCompletedLinear Scar | Zigzag ScarUnited States
-
Wake Forest University Health SciencesCompleted
-
Capstone TherapeuticsCompletedScar Prevention | Scar ReductionUnited States
-
Medstar Health Research InstituteActive, not recruitingBurn Scar | Scar | Skin Graft ScarUnited States
-
Iran University of Medical SciencesRecruitingDry Needling | Scar Tissue | Hypertrophic Scar | Hypertrophic Surgical Scar | Hypertrophic Scar of Upper Arm (Disorder)United States, Iran, Islamic Republic of
-
University of PittsburghUnited States Department of DefenseTerminatedBurn Scar | Restrictive Scar Contracture | Restrictive Hypertrophic Scar | Burn Scar ContracturesUnited States
-
Maternal and Child Health Hospital of FoshanWithdrawn
-
Lumenis Be Ltd.Terminated
-
Assaf-Harofeh Medical CenterNot yet recruiting
-
Maternal and Child Health Hospital of FoshanWithdrawn
Clinical Trials on FAT-GRAFT
-
University of Sao PauloCompletedBreast Reconstruction | Contour Irregularities | Volume InsufficiencyBrazil
-
Ain Shams UniversityCompletedGingival RecessionEgypt
-
Royal Marsden NHS Foundation TrustNot yet recruiting
-
University of PittsburghWithdrawnBreast Cancer | Mastectomy, Segmental | LumpectomyUnited States
-
Odense University HospitalCompletedPost-Mastectomy Chronic Pain Syndrome (Disorder)Denmark
-
University of PittsburghUnited States Department of DefenseTerminatedFacial Injuries | Adipose TissueUnited States
-
Nantes University HospitalNot yet recruitingCrohn Disease | Anal Fistula
-
University of PittsburghRecruiting
-
Ain Shams UniversityCompleted
-
King Edward Medical UniversityUnknownLipodystrophy | Craniofacial Microsomia | Mixed Connective Tissue Disease | Romberg's Disease